Perlmutter Cancer Center

The purpose of this study is to determine whether 177Lu-PSMA-617, given for 6 weeks at a dose of 7.4 GBq improves the radiographic progression free survival or death compared to a change in treatment of androgen receptor-directed therapy (ARTD) in metastatic castrate resistant prostate cancer participants that are previously treated with another ARTD and have not been exposed to taxane-containing regimen. The study drug 177Lu-PSMA-617 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.